Antiangiogenic agents for nonmalignant brain tumors

Journal of Neurological Surgery, Part B: Skull Base

Volumn 74, Issue 3, 2013, Pages 136-141

  Hawasli, Ammar H ^a   Rubin, Joshua B ^a   Tran, David D ^a   Adkins, Douglas R ^a   Waheed, Shahid ^b   Hullar, Timothy E ^a   Gutmann, David H ^a   Evans, John ^a   Leonard, Jeffrey R ^a   Zipfel, Gregory J ^a   Chicoine, Michael R ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b J B and Greeta B Arthur Cancer Center   (United States)

Author keywords

bevacizumab; brain tumor; meningioma; neurofibromatosis; pazopanib; vascular endothelial growth factor; vestibular schwannoma

Indexed keywords

BEVACIZUMAB; PAZOPANIB;

ABDOMINAL PAIN; ACOUSTIC NEURINOMA; ADOLESCENT; ADULT; AGED; ANOREXIA; ARTICLE; BILATERAL CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONFUSION; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG INDUCED DISEASE; EPISTAXIS; FEMALE; HUMAN; HYPERTENSION; MALE; MEDICAL RECORD REVIEW; MENINGIOMA; NAUSEA; NEUROFIBROMATOSIS; PRIORITY JOURNAL; RECURRENT CANCER; RETROSPECTIVE STUDY; SIDE EFFECT; THORAX PAIN; WEIGHT REDUCTION;

EID: 84878763677     PISSN: 2193634X     EISSN: 21936331     Source Type: Journal    
DOI: 10.1055/s-0033-1338262     Document Type: Article

References (18)

1. Pechlivanis I., Wawrzyniak S., Engelhardt M., Schmieder K. Evidence level in the treatment of meningioma with focus on the comparison between surgery versus radiotherapy. A review. J Neurosurg Sci: 2011; 55 4 319 328
2. Louis D. N., Ramesh V., Gusella J. F. Neuropathology and molecular genetics of neurofibromatosis 2 and related tumors. Brain Pathol: 1995; 5 2 163 172
3. Stangerup S. E., Tos M., Caye-Thomasen P., Tos T., Klokker M., Thomsen J. Increasing annual incidence of vestibular schwannoma and age at diagnosis. J Laryngol Otol: 2004; 118 8 622 627 (Pubitemid 39280057)
4. Stangerup S. E., Tos M., Thomsen J., Caye-Thomasen P. True incidence of vestibular schwannoma? Neurosurgery: 2010; 67 5 1335 1340, discussion 1340
5. Plotkin S. R., Stemmer-Rachamimov A. O., Barker F. G. II., et al. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med: 2009; 361 4 358 367
6. Mautner V. F., Nguyen R., Knecht R., Bokemeyer C. Radiographic regression of vestibular schwannomas induced by bevacizumab treatment: sustain under continuous drug application and rebound after drug discontinuation. Ann Oncol: 2010; 21 11 2294 2295
7. Mautner V. F., Nguyen R., Kutta H., et al. Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2. Neuro-oncol: 2010; 12 1 14 18
8. Cayé-Thomasen P., Baandrup L., Jacobsen G. K., Thomsen J., Stangerup S. E. Immunohistochemical demonstration of vascular endothelial growth factor in vestibular schwannomas correlates to tumor growth rate. Laryngoscope: 2003; 113 12 2129 2134 (Pubitemid 38063834)
9. Cayé-Thomasen P., Werther K., Nalla A., et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol: 2005; 26 1 98 101 (Pubitemid 40130217)
10. Preusser M., Hassler M., Birner P., et al. Microvascularization and expression of VEGF and its receptors in recurring meningiomas: pathobiological data in favor of anti-angiogenic therapy approaches. Clin Neuropathol: 2012; 31 5 352 360
11. Preusser M., Spiegl-Kreinecker S., Lötsch D., et al. Trabectedin has promising antineoplastic activity in high-grade meningioma. Cancer: 2012; 118 20 5038 5049
12. Nayak L., Iwamoto F. M., Rudnick J. D., et al. Atypical and anaplastic meningiomas treated with bevacizumab. J Neurooncol: 2012; 109 1 187 193
13. Lou E., Sumrall A. L., Turner S., et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol: 2012; 109 1 63 70
14. Wang P., Ni R. Y., Chen M. N., Mou K. J., Mao Q., Liu Y. H. Expression of aquaporin-4 in human supratentorial meningiomas with peritumoral brain edema and correlation of VEGF with edema formation. Genet Mol Res: 2011; 10 3 2165 2171
15. Matuschek C., Bölke E., Nawatny J., et al. Bevacizumab as a treatment option for radiation-induced cerebral necrosis. Strahlenther Onkol: 2011; 187 2 135 139
16. Genentech I. Highlights of prescribing information: Avastin. 2011; http://www.gene.com/download/pdf/avastin-prescribing.pdf
17. Hwang E. I., Jakacki R. I., Fisher M. J., et al. Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. Pediatr Blood Cancer: 2012
18. Packer R. J., Jakacki R., Horn M., et al. Objective response of multiply recurrent low-grade gliomas to bevacizumab and irinotecan. Pediatr Blood Cancer: 2009; 52 7 791 795